We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Enhanced Cell-Based Blood Tests to Improve Predictive Accuracy for Complex Transplant Outcomes

By LabMedica International staff writers
Posted on 04 Aug 2025

Managing immunosuppressive drugs in transplant patients is a delicate challenge. More...

Insufficient medication can lead to rejection, which may be cell- or antibody-mediated, while excess immunosuppression raises the risk of infection and complications such as Epstein-Barr virus (EBV)-associated lymphoma. Current diagnostic tools provide limited insight into a patient’s immune status, relying on reactive, binary results. Clinicians often must combine various sources of clinical data to make critical decisions, making a timely and accurate diagnosis difficult. Now, the integration of artificial intelligence (AI) and machine learning (ML) capabilities with cell-based blood tests could significantly improve predictive accuracy for complex transplant outcomes.

Plexision (Pittsburgh, PA, USA) is advancing personalized transplant medicine using AI-enhanced cell-based testing. Plexision’s suite of cell-based blood tests predicts the most common rejection subtypes and post-transplant infections, all using a common platform of immune cell function. The company is further enhancing the platform’s predictive accuracy, enabling it to rank the likelihood of several outcomes such as stable graft function, T-cell-mediated and antibody-mediated rejection, and infection-related lymphoma. The platform delivers results in as little as 6 to 24 hours and transforms test results from binary outputs to ranked, patient-specific predictions, allowing for more tailored clinical decisions.

The platform has demonstrated strong clinical performance in multi-center studies. For instance, PlexABMR, one of the company’s tests, predicted antibody-mediated rejection in kidney transplant recipients with 81% positive predictive value and 75% negative predictive value. Another test accurately predicted EBV infection, a leading cause of life-threatening post-transplant lymphoma. Moving forward, Plexision aims to continue advancing its AI-driven capabilities and expand its impact in precision transplant care by delivering timely, individualized insights to clinicians managing high-risk transplant patients.

“Plexision is redefining transplant diagnostics by predicting rejection subtypes and infection risks using blood tests derived from a single immune cell function platform,” said Dr. Rakesh Sindhi, a transplant surgeon, Co-founder and Chief Scientific Officer, Plexision. "By expanding our artificial intelligence and machine learning capabilities, we are transforming how clinicians will interpret immunologic signals, moving from singular binary ‘yes/no’ answers to ranked predictions tailored to each patient.”

Related Links:
Plexision


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette
Accumax Smart Series
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.